Cancer stem cells: An innovative therapeutic approach

Advances in Cancer Stem Cell Biology

Volumn , Issue , 2012, Pages 239-266

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Pontoglio, Alessandro ^a   Scarà, Salvatore ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949175529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0809-3_15     Document Type: Chapter

References (117)

1. Agrawal M, Garg RJ, Cortes J, Quintas-Cardama A. (2010). Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 5: 70-80
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-88
3. Amann M, D'Argouges S, Lorenczewski G, et al. (2009). Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-Term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 32: 452-64
4. Atadja PW. (2011). HDAC inhibitors and cancer therapy. Prog Drug Res 67: 175-95
5. Baeuerle PA, Kufer P, Bargou R. (2009). BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 11: 22-30
6. Bjerkvig R, Tysnes BB, Aboody KS, et al. (2005). Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5: 899-904
7. Blair A, Hogge DE, Ailles LE, et al. (1997). Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-Term proliferative ability in vitro and in vivo. Blood 89: 3104-12
8. Bolos V, Grego-Bessa J, de la Pompa JL. (2007). Notch signaling in development and cancer. Endocr Rev 8: 339-63
9. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-7
10. Bos CL, Kodach LL, van den Brink GR, et al. (2006). Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25: 6447-56
11. Bottom P, Giardina B, Martorana GE, et al. (2005). A two-dimensional electrophoresis preliminary approach to human hepatocarcinoma differentiation induced by PPAR-Agonists. J Cell Mol Med 9: 462-7
12. Brennan SK, Wang Q, Tressler R, et al. (2010). Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS One 5: e12487
13. Brischwein K, Schlereth B, Guller B, et al. (2006). MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 43: 1129-43
14. Bross PF, Beitz J, Chen G, et al. (2001). Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7: 1490-6
15. Butler JM, Kobayashi H, Rafii S. (2010). Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10: 138-46
16. Cantley L, Carpenter CL. (2008). Cell Signaling. In: Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology, 8th edn. Lippincott Williams & Wilkins, Philadelphia
17. Castelo-Branco P, Zhang C, Lipman T, et al. (2011). Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition. Clin Cancer Res 17: 111-21
18. Charrad RS, Gadhoum Z, Qi J, et al. (2002). Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 99: 290-9
19. Chen KH, Hsu CC, Song WS, et al. (2010). Celecoxib enhances radiosensitivity in medulloblastomaderived CD133-positive cells. Childs Nerv Syst 26: 1605-12
20. Chen X, Deng Y. (2009). Simulations of a specific inhibitor of the dishevelled PDZ domain. J Mol Model 15: 91-6
21. Clarke WT, Marks PW. (2010). Gemtuzumab ozogamicin: is there room for salvage? Blood 116: 2618-9
22. Croom KF, Perry CM. (2003). Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 63: 513-22
23. Deng L, Hu S, Baydoun AR, et al. (2009). Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway. Cell Prolif 42: 721-30
24. Deng Y, Chan SS, Chang S. (2008). Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 8: 450-8
25. Deonarain MP, Kousparou CA, Epenetos AA. (2009). Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 1: 12-25
26. Diaz R, Nguewa PA, Parrondo R, et al. (2010). Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer 10: 188
27. Dick JE. (2008). Stem cell concepts renew cancer research. Blood 112: 4793-807
28. Doggrell SA. (2010). The hedgehog pathway inhibitor GDC-0449 shows potential in skin and other cancers. Expert Opin Investig Drugs 19: 451-4
29. Emami KH, Nguyen C, Ma H, et al. (2004). A small molecule inhibitor of beta-catenin/CREBbinding protein transcription. Proc Natl Acad Sci USA 101: 12682-7
30. Entimov VJ, Brown TJ. (2010). Evaluation of activated CD44 as a biological target in the eradication of breast cancer stem cells. Cancer Stem Cell Therapeutics, American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC 2010
31. Entimov VJ, BrownTJ. (2010). HA-Irinotecan targeting of activated CD44 is an effective therapy for the eradication of putative colon cancer stem cells. Cancer Stem Cell Therapeutics, American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC 2010
32. Fletcher JI, Haber M, Henderson MJ, Norris MD. (2010). ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10: 147-56
33. Gadhoum Z, Delaunay J, Maquarre E, et al. (2004). The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 45: 1501-10
34. Gires O, Klein CA, Baeuerle PA. (2009). On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9: 143
35. Griffero F, Daga A, Marubbi D, et al. (2009). Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 284: 7138-48
36. Gupta PB, Chaffer CL, Weinberg RA. (2009). Cancer stem cells: mirage or reality? Nat Med 15: 1010-2
37. Gupta PB, Onder TT, Jiang G, et al. (2009). Identification of selective inhibitors of cancer stem cells by high-Throughput screening. Cell 138: 645-59
38. Halsen G, Kramer I. (2010). Assessing the risk to health care staff from long-Term exposure to anticancer drugs-The case of monoclonal antibodies. J Oncol Pharm Pract, Jul 28
39. He B, Lee AY, Dadfarmay S, et al. (2005). Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65: 743-8
40. He B, You L, Uematsu K, et al. (2004). A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6: 7-14
41. Hidalgo M, Maitra A. (2009). The Hedgehog Pathway and Pancreatic Cancer. N Engl J Med 361: 2094-6
42. Hoey T, Yen WC, Axelrod F, et al. (2009) 1DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency. Cell Stem Cell 5: 168-177
43. Jin L, Hope KJ, Zhai Q, et al. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2: 1167-74
44. Jin L, Lee EM, Ramshaw HS, et al. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31-42
45. Jordan CT, Upchurch D, Szilvassy SJ, et al. (2000). The interleukin-3 receptor a chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-84
46. Joseph I, Tressler R, Bassett E, et al. (2010). The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 70: 9494-504
47. Kang KB, Wang TT, Woon CT, et al. (2007). Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67: 888-96
48. Katayama R, Koike S, Sato S, et al. (2009). Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci 100: 2060-8
49. Khanim FL, Hayden RE, Birtwistle J, et al. (2009). Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One. 4: e8147
50. Kim H, Won S, Hwang DY, et al. (2010). Downregulation of Wnt/beta-catenin signaling causes degeneration of hippocampal neurons in vivo. Neurobiol Aging doi: 10.1016/j.neurobiolaging. 2010.03.013 |
51. King PJ, Guasti L, Laufer E. (2008). Hedgehog signalling in endocrine development and disease. J Endocrinol 198: 439-50
52. KitazaM T, Oka M, Nakamura Y, et al. (2005). Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-43
53. Koch U, Radtke F. (2010). Notch signaling in solid tumors. Curr Top Dev Biol 92: 411-55
54. Koppe M, Schaijk F, Roos J, et al. (2004). Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzuma) in patients with early-stage breast cancer. Cancer Biother Radiopharm 19: 720-9
55. LaBarge MA. (2010). The difficulty of targeting cancer stem cell niches. Clin Cancer Res 16: 3121-9
56. Levitzki A. (2002). Tyrosine kinases as targets for cancer therapy. Eur J Cancer 38 Suppl 5: S11-8
57. LoRusso PM, Ryan AJ, Boerner SA. (2008). Small Molecule Tyrosine Kinase Inhibitors. In Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology 8th Edn. Williams & Wilkins, Philadelphia
58. Luistro L, He W, Smith M, et al. (2009). Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69: 7672-80
59. Marangoni E, Lecomte N, Durand L, et al. (2009). CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer 100: 918-22
60. Marian CO, Cho SK, McEllin BM, et al. (2010). The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16: 154-63
61. Marks PA. (2007). Discovery and development of SAHA as an anticancer agent. Oncogene 26: 1351-6
62. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, et al. (2008). Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10: 395-8
63. Massard C, Deutsch E, Soria JC. (2006). Tumour stem cell-Targeted treatment: elimination or differentiation. Ann Oncol 17: 1620-4
64. Merchant AA, Matsui W. (2010). Targeting Hedgehog-A cancer stem cell pathway. Clin Cancer Res 16: 3130-40
65. Mimeault M, Johansson SL, Henichart JP, et al. (2010). Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and non side population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther 9: 617-30
66. Mittal S, Mifflin R, Powell DW. (2009). Cancer stem cells: the other face of Janus. Am J Med Sci 338: 107-12
67. Munz M, Baeuerle PA, Gires O. (2009). The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69: 5627-9
68. Murphy CG, Former M. (2010). HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 24: 410-5
69. Murray JA, Khanim FL, Hayden RE, et al. (2010). Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol 149: 65-9
70. Mustjoki S, Rohon P, Rapakko K, et al. (2010). Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia 24: 219-22
71. Naka K, Hoshii T, Hirao A. (2010). Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 101: 1577-81
72. Neyns B, Sadones J, Chaskis C, et al. (2010). Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol Sep 25
73. Nowak D, Stewart D, Koeffler HP. (2009). Differentiation therapy of leukemia: 3 decades of development. Blood 113: 3655-65
74. Osada T, Hsu D, Hammond S, et al. (2010). Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 102: 124-33
75. O'Sullivan B, Thomas R. (2004). Recent advances on the role of CD40 and dendritic cells in immunity and tolerance. Curr Opin Hematol 10: 272-8
76. Pannuti A, Foreman K, Rizzo P, Osipo C (2010). Targeting Notch to Target Cancer Stem Cells . Clin Cancer Res 16: 3141-52
77. Phay JE, Shah MH. (2010). Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res 16: 5936-41
78. Ramalingam SS, Belani CP, Mack PC, et al. (2010). Phase II study of Cediranib (AZD 2171), an inhibitor ofthe vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 5: 1279-84
79. Razavi R, Gehrke I, Gandhirajan RK, et al. (2011). Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong anti-Tumor efficacy in vivo. Clin Cancer Res 2011: published online 11 January, doi: 10.1158/1078-0432
80. Redova M, Chlapek P, Loja T, et al. (2010). Influence of LOX/COX inhibitors on cell differentiation induced by all-Trans retinoic acid in neuroblastoma cell lines. Int J Mol Med 25: 271-80
81. Reya T, and Clevers H. (2005). Wnt signalling in stem cells and cancer. Nature 434: 843-850
82. Riccioni R, Dupuis ML, Bernabei M, et al. (2010). The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 45: 86-92
83. Roccaro AM, Leleu X, Sacco A, et al. (2008). Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res 14: 1849-58
84. Roesler R, Cornelio DB, Abujamra AL, Schwartsmann G. (2010). HER2 as a cancer stem-cell target. Lancet Oncol 11: 225-6
85. Rosato RR, Grant S. (2004). Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13: 21-38
86. Rudin CM, Hann CL, Laterra J, et al. (2009). Low JA.Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361: 1173-8
87. Rupp U, Schoendorf-Holland E, Eichbaum M, et al. (2007). Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anticancer Drugs 18: 477-85
88. Scatena R, Bottom P, Giardina B. (2008). Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key? PPAR Res 2008: 256251
89. Scatena R, Bottom P, Giardina B. (2008). Modulation of cancer cell line differentiation: A neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin Appl 2: 229-37
90. Scatena R, Bottom P, Pontoglio A, Giardina B. (2010). Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy. Proteomics Clin Appl 4: 143-58
91. Scatena R, Bottom P, Pontoglio A, Giardina B. (2011). Cancer stem cells: the development of new cancer therapeutics. Expert Opin Biol Ther. Mar 30
92. Schuler M, et al. (2008). First results from a phase Ib study of the anti-EpCAM antibody adecatumumab (MT201) in combination with docetaxel in patients with metastatic breast cancer. Annual Meeting of ESMO, Abstract No. 485p
93. Shackleton M, Quintana E, Fearon ER, Morrison SJ. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138: 822-9
94. Shojaei F, Lee JH, Simmons BH, et al. (2010). HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 70: 10090-100
95. Singh B, Cook KR, Vincent L, et al. (2010). Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line. J Surg Res: published online 26 Mar 2010 doi: 10.1016/j.jss.2010.03.003
96. So PL, Tang JY, Epstein EH. (2010). Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs 19: 1099-112
97. Subramaniam V, Vincent IR, Gilakjan M, Jothy S. (2007). Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 83: 332-40
98. Takahashi-Yanaga F, Kahn M. (2010). Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16: 3153-62
99. Tang C, Ang BT, Pervaiz S. (2007). Cancer stem cell: target for anti-cancer therapy. FASEB J 21: 3777-85
100. Tao LY, Liang YJ, Wang F, et al. (2009). Cediranib (recentin, AZD2171) reverses ABCB1-And ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 64: 961-9
101. Trumpp A, Wiestler OD. (2008). Mechanisms of Disease: cancer stem cells-Targeting the evil twin. Nat Clin Pract Oncol 5: 337-47
102. van der Heijden MS, Bernards R. (2010). Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 16: 3094-9
103. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. (2010). Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1 R/Wnt and activation of p53 signaling pathways. BMC Cancer 10: 238
104. Von Hoff DD, LoRusso PM, Rudin CM, et al. (2009). Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361: 1164-72
105. Wang JCY, Dick JE. (2008). Cancer Stem Cells. In: Devita, Hellman & Rosenberg's Cancer: Principles & Practice of Oncology 8th Edn. Lippincott Williams & Wilkins, Philadelphia
106. Wang Y, Chen X, Zhu W, et al. (2006). Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. Clin Exp Pharmacol Physiol 33: 696-701
107. Wei P, Walls M, Qiu M, et al. (2010). Evaluation of selective gamma-secretase inhibitor PF-03084014for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9: 1618-28
108. Wicha MS. (2009). Targeting breast cancer stem cells. Breast 18 Suppl 3: S56-8
109. Wu Y, Cain-Hom C, Choy L, et al. (2010). Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1059
110. Yauch RL, Dijkgraaf GJ, Alicke B, et al. (2009). Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326: 572-4
111. Yin L, Velazquez OC, Liu ZJ. (2010). Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol 80: 690-701
112. You L, He B, Xu Z, et al. (2004). An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64: 5385-9
113. Younus J, Verma S, Franek J, Coakley N. (2010). Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence. Curr Oncol 17: 4-10
114. Zama IN, Hutson TE, Elson P, et al. (2010). Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116: 5400-6
115. Zheng LS, Wang F, Li YH, et al. (2009). Vandetanib (Zactima, ZD6474) antagonizes ABCC1-And ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 4: e5172
116. Zhou BB, Zhang H, Damelin M, et al. (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-23
117. Zibat A, Missiaglia E, Rosenberger A, et al. (2010). Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 29: 6323-30